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Sheila J. Sadeghi, Gianluca Catucci and Gianfranco Gilardi *
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Human liver cytochrome P450 3A4 is the main enzyme involved in drug metabolism.
This makes it an attractive target for biocatalytic applications, such as the synthesis
of pharmaceuticals and drug metabolites. However, its poor solubility, stability and
low coupling have limited its application in the biotechnological context. We previously
demonstrated that the solubility of P450 3A4 can be increased by creating fusion proteins
between the reductase from Bacillus megaterium BM3 (BMR) and the N-terminally
modified P450 3A4 (3A4-BMR). In this work, we aim at increasing stability and coupling
efficiency by varying the length of the loop connecting the two domains to allow higher
inter-domain flexibility, optimizing the interaction between the domains. Starting from
the construct 3A4-BMR containing the short linker Pro-Ser-Arg, two constructs were
generated by introducing a 3 and 5 glycine hinge (3A4-3GLY-BMR and 3A4-5GLY-BMR).
The three fusion proteins show the typical absorbance at 450 nm of the reduced
heme-CO adduct as well as the correct incorporation of the FAD and FMN cofactors.
Each of the three chimeric proteins were more stable than P450 3A4 alone. Moreover,
the 3A4-BMR-3-GLY enzyme showed the highest NADPH oxidation rate in line with the
most positive reduction potential. On the other hand, the 3A4-BMR-5-GLY fusion protein
showed a Vmax increased by 2-fold as well as a higher coupling efficiency when compared
to 3A4-BMR in the hydroxylation of the marker substrate testosterone. This protein also
showed the highest rate value of cytochrome c reduction when this external electron
acceptor is used to intercept electrons from BMR to P450. The data suggest that the
flexibility and the interaction between domains in the chimeric proteins is a key parameter
to improve turnover and coupling efficiency. These findings provide important guidelines
in engineering catalytically self-sufficient human P450 for applications in biocatalysis.
Keywords: P450 biocatalysis, domain interaction, glycine linker, stability, uncoupling, electron transfer
INTRODUCTION
Cytochromes P450 are heme-thiolate monooxygenases found in all domains of life (Coon, 2005;
Bernhardt, 2006) able tometabolize several endogenousmolecules and xenobiotics, including drugs
(Nelson et al., 1996; Ortiz de Montellano, 2005; Isin and Guengerich, 2007).
They catalyze many chemical reactions such as hydroxylation of non-activated carbon atoms,
epoxidation of double bonds and dealkylation on C-, N-, and S- atoms (Isin and Guengerich, 2007).
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Electrons for these reactions are provided by NADPH and
transferred to the heme cofactor via different redox partners
classified by Hannemann et al. (2007). Thus, NADPH is used as
electron source and in the presence of molecular oxygen, reaction
product(s) can be generated in single or multistep reactions.
Although the human liver enzymes are an attractive
biotechnological target in their use as biocatalysts for their ability
to produce pharmaceuticals and drug metabolites, limitations are
given by poor stability and by the so-called “uncoupling,” the
formation of reactive oxygen species at the heme site leading
to the release of intermediates such as superoxide and peroxide
during the reaction cycle (Guengerich, 2002; Meunier et al., 2004;
Zangar et al., 2004; Denisov et al., 2005). The uncoupling process
can lead to a loss of NADPH redox equivalents as high as 99% in
human cytochrome P450 1A2 (Mayuzumi et al., 1993) or 16% for
3A4 (Perret and Pompon, 1998) and it can be seen as a wasteful
process. These high uncoupling levels, together with the need of
a reductase, are a considerable disadvantage in the use of human
enzymes as biocatalysts.
On the other hand, bacterial P450 enzymes are known to
be well coupled and as in the case of P450 BM3 from Bacillus
megaterium, have been shown to be able to produce drug
metabolites typical of the human enzymes with a high coupling
efficiency (Di Nardo et al., 2007; Di Nardo and Gilardi, 2012).
This has led to a wide range of protein engineering studies on this
enzyme to widen its catalytic abilities (Tsotsou et al., 2012, 2013;
Ryu et al., 2014; Di Nardo et al., 2015; Ren et al., 2015; Capoferri
et al., 2016).
One factor that makes P450 BM3 a well-coupled biocatalyst
resides in the productive interaction between the heme catalytic
domain (BMP) and its flavin-containing reductase domain
(BMR) that, unlike in other cytochromes P450, are all part of
the same polypetide chain. For this reason we already reported
the construction of different fusion human P450 enzymes,
engineered by connecting the reductase domain BMR with
human cytochromes P450 2E1(Fairhead et al., 2005), 3A4,
2C9, 2C19 (Dodhia et al., 2006), 2A6, CYP2C6, and CYP4F11
(Ortolani, 2012; Rua, 2012a; Castrignanò et al., 2014), monkey
2C20 (Rua et al., 2012b) and dog CYP2D15 (Sadeghi and Gilardi,
2013; Rua et al., 2015).
As human cytochrome P450 3A4 is responsible for the
metabolism of the majority of commercial drugs and it is at the
origin of many drug-drug interactions of clinical concern (Evans
and Relling, 1999), we further characterized the parameters
influencing uncoupling in the reconstituted fusion protein P450
3A4-apo-BMR, such as flavin content, substrate, and NADPH
concentration, pH and ionic strength (Degregorio et al., 2011).
Among P450 systems, P450 BM3 is considered as a model for
self-sufficiency and high coupling efficiency (Munro et al., 1996;
Noble et al., 1999). In 2005, Neeli and colleagues suggested
that BM3 fatty acid hydroxylation activity can be related to a
dimeric form of the enzyme and for this protein electron transfer
is achieved through an “inter subunits” interaction between
protomers rather than direct flow between the di-flavin and the
heme held by the same polypeptide chain (Neeli et al., 2005).
In the present work we consider another parameter that
can influence the coupling efficiency in the fusion protein
P450 3A4-BMR: the length of the loop linking the oxygenase
domain with the reductase one. In 1995, Govindaraj and Poulos
demonstrated that the length of the linker is the critical feature
that controls flavin-to-heme electron transfer in cytochrome
P450 BM3 (Govindaraj and Poulos, 1995). Moreover, the role of
the linker sequence in facilitating the ability of cyt b5 to reduce
P450 2B4 was explored by altering the length and sequence of the
flexible linker region between the heme domain and membrane
anchor of cyt b5 (Clarke et al., 2004). Clarke and co-workers
demonstrated that, although the sequence of the linker region can
be varied without significant effects on the properties of cyt b5,
the linker region has a critical minimum length of 6–8 residues.
Here we aim at elucidating first if then how the length of the
linker connecting the reductase and catalytic domain in the 3A4-
BMR fusion protein has an effect in modulating the activity and
the uncoupling process.
Flexibility between protein domains is a critical parameter in
modulating the uncoupling process via the formation of an active
complex and by tuning the electron flow to the heme. The ability
of the reductase of P450 BM3 from B. megaterium (BMR) to
transfer electrons in the redox chain fromNADPH to the heme is
evaluated by varying the length of the linker region between BMR
and the N-terminally modified 3A4 heme domain. As shown in
Figure 1, the BMR and P450 3A4 domains possess the surface
charges complementarity that is known to be more crucial for the
complex formation than when the physiological redox partner,
cytochrome P450 reductase (hCPR) was used instead. In order
for catalysis to occur, this active complex should form with high
propensity. Thus, starting from the 3A4-BMR chimera in which
the BMR domain is linked to the 3A4 via the short linker Pro-
Ser-Arg, two new constructs are engineered to include 3- or
5-Gly inserted after the Pro-Ser-Arg loop leading to 3A4-3GLY-
BMR and 3A4-5GLY-BMR chimeric proteins. This glycine rich
region close to the C-terminal of P450 3A4 has been proposed
to function as a flexible hinge that can provide the enzyme the
degrees of freedom required to achieve a functional complex. The
effect of the linker length on the electron transfer between the
reductase and the catalytic domains in the presence of NADPH
as electron supplier is studied for the three chimeras.
The electrons delivery from NADPH to the flavins of the
reductase domainis is evaluated in the three complexes by
anaerobic stopped flow spectroscopy measurement of NADPH
consumption rate in the absence of substrate. The electron
transfer capability of reducing equivalents by flavins of the
reductase domain is investigated using cyt c as an artificial
electron acceptor (Guengerich et al., 2009) and the effect
of the linker length is examined. Finally, the ability of the
BMR to sustain catalysis at the 3A4 catalytic domain is
explored in relation to the length of the linker by investigating
enzyme activity and coupling efficiency during erythromycin
N-demethylation and testosterone 6β-hydroxylation.
MATERIALS AND METHODS
Chemicals and Reagents
The pCW-3A4-BMR plasmid containing the gene of human
P450 3A4 fused to the reductase of cytochrome P450 BM3
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FIGURE 1 | (A) Surface charge distribution of P450 3A4 (left, PDB ID 1TQN) and the FMN binding domain of P450 BM3 (right, PDB ID 1BVY). Heme and FMN are
shown in black. (B) Complex between P450 3A4 and the FMN binding domain of BMR. The complex was created by super-imposition of the crystal structure of P450
3A4 with the heme domain of P450 BM3 in the complex crystal structure.
from B. megaterium (BMR) linked via a Pro-Ser-Arg linker
was available in our laboratory (Dodhia et al., 2006). GenElute
plasmid miniprep kit was obtained from Sigma (Italy). PCR
purification kit and gel extraction kit were purchased from
Macherey-Nagel (Germany).
The primers for PCR and oligonucleotides for the linker
region between P450 3A4 and BMR reductase were prepared
by MWG (Germany). DNA Ladder, restriction endonucleases
enzymes Avr II and Hind III, Vent polymerase, T4 DNA ligase
enzyme and buffers used in sub-cloning were from New England
Biolabs (UK) and Promega (Italy). Horse heart cytochrome c,
erythromycin, testosterone, 6β-hydroxytestosterone, horseradish
peroxidase type X, superoxide dismutase from bovine
erythrocytes, catalase, N,N-dimethylaniline, and 4-amino-
2,3-dimethyl-1-phenyl-3-pyrazolin-5-one were purchased from
Sigma (Italy). NADPH (tetrasodium salt) was acquired from
Calbiochem (Germany). Human CPR was purchased from Life
Technologies. All other chemicals, biochemicals used in this
study were purchased from Sigma (Italy) at the highest available
grade and used as recommended by the manufacturer.
Engineering the Linkers in the 3A4-BMR
Chimeras
The strategy used in the construction of the fusion proteins is
based upon introduction of 3 or 5 glycines in the pre-existent
Pro-Ser-Arg linker connecting P450 CYP 3A4 domain and BMR
one domain via 3 amino acids (Pro-Ser-Arg) by using as a starting
template the vector pCW-3A4-BMR available in our laboratory
(Figure 2A; Dodhia et al., 2006). Glycine was chosen to allow
the highest flexibility of the loop to support conformational
rearrangements between the two domains as much as possible.
All PCR reactions were performed in a DNA thermal
cycler (PerkinElmer Life Sciences, Italy) and employed Vent
polymerase under conditions recommended by themanufacturer
(Promega, Italy).
The 3A4-3GLY-BMR chimera was engineered to contain the
N-terminally modified human P450 CYP 3A4 (aa 13-503), the
linker Pro-Ser-Arg-Gly-Gly-Gly and the C-terminal reductase
(aa 472-1049) of P450 BM3 from B. megaterium. The 3A4-
5GLY-BMR chimera contains the N-terminally modified human
P450 3A4 (aa 13-503), the linker Pro-Ser-Arg-Gly-Gly-Gly-
Gly-Gly and the C-terminal reductase domain (aa 472-1049)
of B. megaterium. The gene coding for the BMR reductase
was amplified using the forward 5-AGTGGAGCCCCTAGG
TCAGGCGGTGGCAAAAAGGCAGAAAACGCTCATAAT-3′
and reverse 5′-GCTCATGTTTGACAGCTTATCATCGAT
AAGCTTTTACCC-3′ primers for the chimera with 3 glycines.
The forward 5′-AGTGGAGCCCCTAGGTCAGGCGGT
GGCGGTGGCAAAAAGGCAGAAAACGCTCATAAT-3′ and
reverse 5′-GCTCATGTTTGACAGCTTATCATCGATAAGCTT
TTACCC-3′ primers were used for the 5-glycine chimera. The
forward primers were synthesized with an overhanging Hind
III restriction site upstream of the BMR start codon, whereas
the reverse primers contained an Avr II site downstream of the
stop codon. The underlined letters represent the endonuclease
restriction sites. DNA was melted for 2min at 94◦C, followed
by 30 cycles of 1min at 94◦C, 1min and 45 s at 60◦C, 1min at
72◦C. The polymerase chain reaction products obtained were
digested with Hind III and Avr II endonucleases and purified by
the GeneClean II method as described by the manufacturer. The
pCW-3A4-BMR vector was digested for 1 h at 37◦C with Hind
III and Avr II and genomic DNA corresponding to pCW-3A4
was isolated by NAGEL KIT extraction and then ligated using
T4 DNA ligase with the sticky sites of the digest PCR products.
The ligation mix was transformed into E. coli DH5α cells and
plated on LB agar containing 100µg/ml ampicillin. The positive
clones were chosen and the plasmid DNA was purified using
a Mini-prep plasmid extraction kit (Sigma, Italy). The correct
insertion of the glycine codons was verified by DNA sequencing.
Expression, Purification, and
Characterization
Heterologous expression of 3A4-BMR, 3A4-3GLY-BMR, and
3A4-5GLY-BMR was performed by transforming competent
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FIGURE 2 | (A) Schematic illustration of the chimeras construction strategy. (B) SDS-PAGE of the purified chimeric proteins.
E. Coli DH5α cells with the corresponding plasmid vectors.
The proteins were purified using diethylaminoethyl and
hydroxylapatite columns as described before (Dodhia et al.,
2006). The purity of the enzymes was checked by sodium dodecyl
sulfate polyacrylamide gel electrophoresis on 7.5% gel using a
Mini-Protean apparatus (Bio-Rad, USA) with Coomassie blue
staining.
Protein concentrations were determined from the absorption
at 450 nm of the carbon monoxide-bound reduced form by using
the Omura and Sato method (Omura and Sato, 1964) using
an extinction coefficient of 91mM−1 cm−1. Protein reduction
was achieved by addition of saturating sodium dithionite,
and formation of the carbon monoxy-adduct of the heme
was obtained by bubbling the reduced enzyme with carbon
monoxide.
Determination of the Heme and Flavin
Contents
The ratio protein:heme:FMN:FAD were calculated using
different spectroscopic methods. Protein concentration was
estimated using Bradford assay (Bradford, 1976), while the
heme concentration was obtained from the CO-binding
assay described above (Omura and Sato, 1964). FAD and
FMN contents were calculated using fluorescence emission
spectroscopy in each purified enzymes (Faeder and Siegel, 1973).
Excitation at 450 nm produced fluorescence emission spectra
with an emission maximum at 535 nm as expected for flavin-
containing proteins. Quantification of FAD and FMN present in
the protein is based on the different behavior of the two cofactors
at different pH-values (Aliverti et al., 1999). The samples were
boiled for 3min to release the flavins, then rapidly cooled on ice
and centrifuged at 14,000 g for 10min. An aliquot of the clear
supernatant was diluted with standard buffer (0.1M potassium
phosphate buffer pH 7.7, containing 0.1mM EDTA) so that the
final volume was 1.5mL and the mixture was transferred to a
1 cm path-length fluorimeter cuvette.
Fluorescence emission was recorded at 535 nm; the excitation
wavelength was set at 450 nm. After the initial fluorescence
measurement at pH 7.7, the pH of the solution was adjusted to
2.6 by the addition of 0.1mL of 1 N HCl (final concentration
62.5mM) and the fluorescence was determined again. The
concentrations of FAD and FMN in the supernatant were
determined from the fluorescence intensity compared to those
obtained for standard solutions of flavins by using as extinction
coefficients 11.3 and 12.2mM−1cm−1, respectively (Aliverti et al.,
1999).
Time Dependent Loss of CO-Binding
The stability of 3A4-BMR fusion proteins was compared with
that of CYP 3A4 by following the loss of CO-binding at a
temperature of 37◦C. Recombinant CYP3A4 was expressed and
purified as described byDodhia et al. (2006). CO-binding spectral
assay was performed at 37◦C both in the presence of CYP3A4
and 3A4-BMR chimeric proteins as described in the Section
Determination of the Heme and Flavin Contents by using 1.6µM
protein solutions. The absorbance at 450 nm was followed for
60min by collecting one spectrum every 5min at 37◦C. All the
collected spectra were corrected by subtraction of the spectrum
of the reduced protein and the loss of CO-binding was measured
as a percentage loss in absorbance of the peak at 450 nm.
Anaerobic Stopped Flow
Spectrophotometric Evaluation of NADPH
Consumption
Rates of NADPH oxidation were measured using a Hi-
Tech scientific SF-61 single mixing stopped-flow system (TgK
Scientific, UK) at 25◦C in a glovebox (Belle Technology, UK) with
an oxygen concentration below 10 ppm. NADPH consumption
was monitored at 340 nm (ε = 6.22mM−1 cm−1) for 750 sunder
anaerobic conditions. Proteins and reducing agent solutions (in
the absence and presence of saturating amounts of substrate)
were prepared in syringes in an anaerobic glove box and
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transferred to the sample handling unit of the stopped-flow
instrument. The experiment was performed by mixing the
NADPH (syringe A, 200µM NADPH in 50mM potassium
phosphate buffer pH 8.0) and the enzyme or enzyme plus
substrate solutions (syringe B, 1µMenzyme in 50mMpotassium
phosphate buffer pH 8.0+150µMerythromycin or testosterone).
Analysis of the resulting kinetic data was performed with Kinetic
studio V3 software (TgK Scientific, UK). In order to calculate the
NADPH consumption rate, the plot of absorbance at 340 nm vs.
time was fitted to a single exponential decay function.
Determination of the Reduction Potentials
of the Chimeras
Potentiometric titrations were performed in an anaerobic
glovebox (Belle Technology, UK) with an oxygen concentration
below 10 ppm using a cuvette equipped with a gold laminar
working electrode and an Ag/AgCl reference electrode connected
to a potentiostat controlled by GPES3 software (Ecochemie,
The Netherlands). Ambient reduction potentials were adjusted
by addition of aliquots (2–5µL) of anaerobically freshly
prepared sodium dithionite solution. Titrations were performed
in 50mM potassium phosphate, pH 8. Electrode-solution
mediation was facilitated by adding the following mediators
at 5µM concentration: methyl viologen (Em = −440mV),
benzyl viologen (Em = −359mV), safranine O (Em =
−280mV), anthraquinone-2,6-di sulfonic acid (Em=−185mV),
phenazinemethosulfate (Em = +80mV), methylene blue (Em
= +11mV). The modified cuvette was flushed with oxygen-
free nitrogen before and during the measurements. After
equilibration at each potential, the optical spectrum was
recorded. Reduction of the heme in 3A4-BMR fusion proteins
was followed by the increase in the absorption at 550 nm
related to the merging of Q-bands, using a diode array
spectrophotometer (TgK Scientific, UK). The fraction of reduced
heme, proportional to the measured spectral transition, was
plotted against potential, and the data were fitted to the Nernst
equation:
E = Em + (RT/nF)ln([ox]/[red])
where [ox] and [red] are the concentrations of oxidized and
reduced heme, respectively, E is the solution reduction potential
at equilibrium, n is the number of electrons, Em is the midpoint
potential, F is the Faraday constant, R is the gas constant, and T
is the absolute temperature.
Determination of the Catalytic Activity and
Coupling Efficiency
The enzymatic activity of chimeras was determined
toward erythromycin N-demethylation and testosterone
6β-hydroxylation.
Erythromycin N-demethylation was investigated under
aerobic conditions by quantification of the formaldehyde
arising from the N-demethylation of erythromycin using
the Nash method (Nash, 1953), using a concentration
range of this substrate under 120µM where this molecule
still acts as a substrate. Uncoupling reactions leading to
hydrogen peroxide were determined and quantified using
the N,N-dimethylaniline/4-amino-2,3-dimethyl-1-phenyl-3-
pyrazolin-5-one/crude horseradish peroxidase colorimetric assay
as described by Sugiura et al. (1977). Reactions were carried
out at 37◦C in a 1 cm path length quartz cuvette and consisted
of the following mixture: 0.1M potassium phosphate buffer
pH 8.0, 2% glycerol, 5mM MgCl2, 100mM KCl, 1µM of the
chimeric protein and different concentrations of erythromycin
in the range 0–120µM. For each protein preparation, some
preliminary experiments were performed in order to assess
linearity of reaction rates with respect to time. After blanking
the absorbance at 412 nm with the erythromycin incubated
at 37◦C for 5min with 1µM of the enzymes, catalysis was
initiated by addition of 150µM NADPH. The reactions were
then stopped after 30min by addition of HCl. The samples
were centrifuged at 13,000 rpm for 5min and 0.5mL of the
supernatant were transferred to another tube and mixed with
0.5mL of a concentrated Nash reagent (3 g ammonium acetate,
40µL acetylacetone, 60µL acetic acid in 10mL of water) as
described before (Dodhia et al., 2006).
The reaction linearity was assessed over a 40min time. Thus,
the mixture was incubated at 50◦C for 30min and the samples
were analyzed by measuring absorbance at 412 nm to determine
the formation of formaldehyde. The amount of formaldehyde
produced during the reaction was quantified by using a
calibration curve constructed in the same reaction condition
with a range of concentration between 0 and 30µM. Zero-time
controls were performed in the absence of erythromycin.
Coupling efficiency was calculated as the ratio of
formaldehyde produced during erythromycin N-demethylation
and the total amount of NADPH consumed by the chimeras.
Testosterone 6β-hydroxylation was investigated at 37◦C by
incubating 1µM protein in the presence of testosterone in
a concentration range between 1 and 150µM for 5min.
Catalysis was initiated by addition of 200µM NADPH. The
reaction linearity was assessed over a 40min time. The reactions
were then stopped after 30min by addition of HCl. The
samples were centrifuged at 13,000 rpm for 5min. The amount
of 6β-hydroxytestosterone formed was evaluated by HPLC
coupled with a diode array UV detector (Agilent-1200, Agilent
technologies, USA) equipped with a 4.6 × 250mm, 5µm
C18 column. Testosterone and 6β-hydroxytestosterone were
separated using a gradient elution programmed as follows:
isocratic elution of 20% acetonitrile and 80% water, 0–2min;
linear gradient elution from 20 to 90% acetonitrile and from
80 to 10% water, 2–20min; linear gradient elution from 90 to
20% acetonitrile and from 10 to 80% water, 20–22min; isocratic
elution of 20% acetonitrile and 80% water 22min-end of the
run. The flow rate was set at 1mL/min and detection wavelength
was 244 nm. Retention times were 9.2min and 13.1min for 6β-
testosterone and testosterone, respectively. Coupling efficiency
was calculated as the ratio of 6β-hydroxytestosterone produced
and the total amount of NADPH consumed by the chimeras.
Measurement of Cytochrome c Reduction
by the BMR of the Chimeras
Cytochrome c reduction activity spectrophotometric assay was
performed as described by Guengerich et al. (2009) with slight
modification. In particular, 10µM of cyt c (in 0.1M potassium
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phosphate buffer pH 8.0) were pipetted into a 0.5mL quartz
cuvette (1 cm path-length). Then, 0.1µM of chimeric proteins
were added and gently mixed. The assay was started by adding
NADPH to a final concentration of 75µM. Using the kinetic
mode of the spectrophotometer, the absorbance increase at
550 nm upon cytochrome c reduction was monitored for 5min.
The rate of cytochrome c reduction was calculated using
reduced cyt c extinction coefficient at 550 nm,7.04mM−1cm−1,
as nmol of reduced cyt c per min. The experiment was
carried out both in the absence and in the presence of 20%
glycerol.
Statistical Analysis
All collected data were recorded at least in triplicate and
expressed as mean ± standard deviation. The comparison of the
results obtained was performed by one way ANOVA and two way
ANOVA followed by Student-Newman-Keuls post hoc test using
SigmaPlot software.
RESULTS
Protein Purification and UV-Visible
Properties of the P450 3A4-BMR Chimeras
After expression and purification (Figure 2B), the UV-visible
spectral properties of the purified chimeras were analyzed
between 300 and 600 nm for the oxidized, reduced and carbon
monoxide bound forms. The spectra show the typical features of
both heme and flavin cofactors (Figures 3A–D). These comprise
the characteristic Soret peak at 418 nm corresponding to the
oxidized heme iron, the β and α bands at 535 and 570 nm, the
shoulder around 455–485 nm belonging to the oxidized FAD and
FMN of the BMR domain.
Full reduction of the chimeras was achieved by addition of
excess sodium dithionite leading to the hydroquinone forms with
a concomitant decrease in the intensity in the visible region
spectra (Figures 3A–D, dashed lines). In all cases a clear shift to
450 nm upon CO bubbling indicates the presence of a properly
folded P450 domain (Figures 3A–D, dark gray lines).
The correct stoichiometry of the heme and flavin
incorporation in the chimeras was also investigated by
absorption and fluorescence spectroscopy. The heme content
was determined from the absorbance value at 450 nm of the
CO-adduct and the amount of the total protein was obtained
by Bradford method. In all chimeras the ratio heme:protein
resulted to be close to 1:1 (Table 1). This indicates that the
proteins have a full complement of bound heme cofactor.
The FAD and FMN content was determined by fluorescence
emission spectroscopy as detailed in the materials and methods
section, resulting in a FAD-to-protein and FMN-to-protein
ratio of 0.81 and 0.82 for 3A4-BMR, 0.83, and 0.87 for 3A4-
3GLY-BMR and 0.83 and 0.83 for P450 3A4-5GLY-BMR
(Table 1). The ratios in flavins:heme content suggest that
there is a minimal amount of apoenzyme with a nearly-
stoichiometric amount of each cofactor and indicating that the
domains are independently able to uptake the cofactor while
folding.
NADPH Consumption and Reduction
Potentials of the Heme
Since the inter-domain interactions modulated by the loops
are crucial in determining both the electron transfer rates and
reduction potentials, these parameters were evaluated on the
three chimeras.
Rates of NADPH oxidation by the chimeras were measured by
rapid scanning stopped flow spectrophotometry by following the
decrease in absorbance at 340 nm for 750 s in anaerobic condition
(Sevrioukova et al., 1996; Davydov et al., 2010), as this is the first
essential step in the electron transfer chain involving the FAD and
FMN cofactors of BMR to sustain the 3A4 catalysis (Guengerich,
1983). The NADPH consumption rates were estimated by
fitting the absorbance decrease with single exponential decay
equation both for 3A4-BMR chimeras and for CYP3A4 in
the presence of hCPR as reference system. Moreover, NADPH
oxidation rates were calculated also in the presence of substrate,
erythromycin and testosterone, in saturating conditions. The
results are summarized in the Figure 4. As reported, compared
to CYP3A4/hCPR system, 3A4-BMR chimeric proteins were
found significantly faster both in absence and in presence of
substrate, resulting more efficient in the transfer of reducing
equivalents from NADPH. In addition, 3A4-3GLY-BMR protein
resulted significantly faster in NADPH consumption with respect
to the other two constructs (P < 0.05), both in the presence
and in the absence of substrate. Moreover, the presence of both
erythromycin and testosterone significantly enhances NADPH
consumption rate in all the examined fusion proteins. This effect
is probably due to the fact that the substrate-bound complex has a
higher reduction potential and is capable to accept electrons from
the redox partner more easily leading to a faster reduction of the
heme-Fe3+ to heme-Fe2+ (Sligar et al., 1979; Guengerich, 1983).
Reduction potentials of the heme were determined with
anaerobic spectro-potentiometric titrations of the chimeras
using the method described by Dutton (1978). The change in
population from the oxidized (Fe3+) to the reduced (Fe2+)
state upon addition of sodium dithionite reducing agent was
monitored by observing the spectral transition related to the
merging of the Q-bands in a single band at 550 nm. Reduction
potential values were calculated by plotting the calculated 3A4-
BMR reduced fraction vs. the recorded potential using the
Nernst’s equation. Midpoint potential values were calculated to
be−367± 3mV,−327± 8mV, and−397± 8mV for 3A4-BMR,
3A4-3GLY-BMR and 3A4-5GLY-BMR, respectively.
The differences observed in NADPH oxidation and reduction
potentials indicate that the loops indeed have an impact on these
parameters and therefore also different functional performace in
catalysis are expected.
Stability of the Chimeras
In order to study if and how the length of the loop has an
impact on the stability of the P450 catalytic module, the time
dependent decrease of the absorbance at 450 nm upon reduction
and CO binding was used to compare the relative stability of
P450 proteins (Lin et al., 2005; Foti et al., 2011; Amunugama
et al., 2012). This assay is based on the assumption that the loss
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FIGURE 3 | Left: UV-vis spectra of the purified cytochrome P450 3A4 (A), 3A4-BMR (B), 3A4-3GLY-BMR (C), and 3A4-5GLY-BMR (D) in their oxidized (black
line), reduced (dashed line), and reduced/carbon monoxide-bound (dark gray line) forms. Sodium dithionite completely reduces the flavin cofactors in all enzymes,
leading to spectral bleaching. Binding of carbon monoxide results in the formation of Fe2+-CO complex with heme Soret absorption maxima shifted to 450 nm in all
cases. Right: Time-dependent decrease of the absorbance at 450 nm of the CO-bound cytochrome P450 3A4 (E), 3A4-BMR (F), 3A4-3GLY-BMR (G), and
3A4-5GLY-BMR (H). CO binding loss is significantly higher, in terms of both rate and total absorbance decrease, for CYP 3A4 compared to the three BMR linked
chimeras. Insets: difference spectra generated by subtraction of the reduced P450 spectrum to each Fe2+-CO complex spectrum.
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TABLE 1 | Heme and flavin contents obtained for 3A4-BMR,
3A4-3GLY-BMR, and 3A4-5GLY-BMR.
3A4-BMR 3A4-3GLY-BMR 3A4-5GLY-BMR
Heme content
(nmolheme/nmol protein)
0.97 ± 0.03 0.98 ± 0.01 0.98 ± 0.02
FMN content (nmol
FMN/nmol protein)
0.82 ± 0.01 0.87 ± 0.03 0.83 ± 0.05
FAD content (nmol
FAD/nmol protein)
0.81 ± 0.04 0.83 ± 0.02 0.83 ± 0.02
FIGURE 4 | Anaerobic NADPH oxidation rates for cytochrome P450
3A4-BMR, 3A4-3GLY-BMRand 3A4-5GLY-BMR compared to those
obtained for CYP 3A4 + hCPR system, obtained both in absence (white
bars) and in presence of substrate erythromycin (light gray) and
testosterone (dark gray). Data are mean ± SD for 3 to 6 replicates.
*P < 0.001 compared to CYP 3A4 + hCPR system; #P < 0.05,
##P < 0.001 compared to the protein in absence of substrate; two way
ANOVA.
of the band at 450 nm is associated with a loss of activity of
P450 enzymes (Omura and Sato, 1964). Thus, the absorbance at
450 nm was followed for 60min at 37◦C after the CO-binding
assay for CYP 3A4 as well as the three 3A4-BMR fusion proteins.
The results are shown as percentage residual absorbance in the
Figures 3E–H. Figure 3E shows that 3A4 domain when alone
retains only 10 ± 1% of the initial absorbance at 450 nm with
a loss of 450 nm peak rate of 0.072 ± 0.011min−1, whereas
3A4-BMR (Figure 2F), 3A4-3GLY-BMR (Figure 2G), and 3A4-
5GLY-BMR (Figure 2H) show a higher stability with a residual
absorbance at 450 nm of 42± 7, 30± 1, and 42± 1% respectively
and a loss of 450 nm peak rate of 0.032 ± 0.003min−1, 0.046
± 0.004min−1, and 0.047 ± 0.005min−1 respectively. These
values show that, in these experimental conditions, the stability
is significantly higher for the 3A4-BMR chimeras (P < 0.001,
one way ANOVA) when compared to the 3A4 alone.
Catalytic Properties and Coupling
Efficiency of the Chimeras
Turnover of the different chimeras was studied in the presence
of the substrates erythromycin and testosterone using NADPH
as electron source, and the results are reported in Table 2.
Quantification of both the amount of product formed in
the N-demethylation of erythromycin and coupling efficiency,
determined from the ratio product formed/NADPH oxidized,
were performed for the three chimeras. Erythromycin N-
demethylation rates were calculated at increasing concentration
of the substrate in the presence of all the 3A4-BMR constructs,
and the experimental data were fitted to the Michaelis-Menten
model in order to calculate kinetic parameters (Figure 5A). The
KM-values of 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR
were 20.8 ± 3.6, 27.4 ± 4.0, and 21.3 ± 4.4µM respectively. In
this case no statistically relevant differences were found. These
results show that the glycine linker length does not influence
3A4-BMR affinity for erythromycin substrate, indicating that the
binding pockets of the heme domain of the chimeras are not
perturbed.
Further analysis in terms of turnover rate led to Vmax-values
of 0.0515 ±.0004, 0.1177 ± 0.0006, and 0.1387 ± 0.0009 nmol
min−1 for 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR
(Figure 4B), respectively. In this case, a statistically significant
increase in Vmax for 3A4-3GLY-BMR and 3A4-5GLY-BMR with
respect to the 3A4-BMR construct was observed. This shows
that the glycine linker increases the enzyme turnover rate in
the presence of erythromycin substrate. Moreover, a significant
increase in Vmax-value was found for 3A4-5GLY-BMR compared
to 3A4-3GLY-BMR.
Also the testosterone 6β-hydroxylation rates were calculated
at increasing concentrations of the substrate in the presence of
all the 3A4-BMR constructs, and the results were fitted to the
Michaelis-Menten model in order to calculate kinetic parameters
(Figure 5D). The KM-values obtained from fitting the Michaelis-
Menten curves of 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-
BMRwere 19.6± 2.6, 21.3± 2.7, and 19.8± 2.2µM respectively,
indicating again no statistically relevant differences in the binding
pocket. The Vmax-values were 0.0066± 0.0002, 0.0089± 0.0002,
and 0.0113 ± 0.0003 nmol min−1 respectively for 3A4-BMR,
3A4-3GLY-BMR, and 3A4-5GLY-BMR enzymes (Figure 5E). As
observed in the presence of erythromycin, when comparing
Vmax results, a statistically significant increase was found for
3A4-3GLY-BMR and 3A4-5GLY-BMR with respect to the 3A4-
BMR construct. Also in this case the glycine linker increases the
enzyme turnover rates, with a significant higher Vmax-value for
3A4-5GLY-BMR compared to 3A4-3GLY-BMR.
The coupling efficiency percentage during erythromycin N-
demethylation, calculated as ratio of HCHO formed andNADPH
consumed, were found to be 9.4 ± 0.5, 10.0 ± 0.8, and 12.5
± 0.9% for 3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR,
respectively (Figure 5C). When performing statistical analysis of
these results, the 3A4-5GLY-BMR fusion protein was foundmore
coupled than the other two constructs, whereas no significant
difference was found when comparing 3A4-BMR and 3A4-3GLY-
BMR. A similar comparison was also performed for testosterone
catalysis by calculating coupling efficiency as the ratio of
the amount of 6β-hydroxytestosterone formed and NADPH
consumed. The calculated coupling efficiency percentage ratios
were found to be 3.4 ± 0.1, 4.6 ± 0.1, and 5.8 ± 0.2% for
3A4-BMR, 3A4-3GLY-BMR, and 3A4-5GLY-BMR, respectively
(Figure 5F).
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TABLE 2 | Catalysis and uncoupling parameters for erythromycin N-demethylation and testosterone 6β-hydroxylation for 3A4-BMR, 3A4-3GLY-BMR, and
3A4-5GLY-BMR.
Erythromycin N-demethylation Testosterone 6β-hydroxylation
KM(µM) Vmax(nmol min
−1) Coupling efficiency%(a) KM(µM) Vmax (nmol min
−1) Coupling efficiency%(b)
3A4-BMR 20.8 ± 3.6 0.0515 ± 0.0004 9.4 ± 0.5 19.6 ± 2.6 0.0066 ± 0.0002 3.4 ± 0.1
3A4-3GLY-BMR 27.4 ± 4.0 0.1177 ± 0.0006 10.0 ± 0.8 21.3 ± 2.7 0.0089 ± 0.0002 4.6 ± 0.1
3A4-5GLY-BMR 21.3 ± 4.4 0.1387 ± 0.0009 12.5 ± 0.9 19.8 ± 2.2 0.0113 ± 0.0003 5.8 ± 0.2
Coupling parameters are determined at saturating erythromycin (120µM) and testosterone(150µM) concentrations. Values are means ± standard deviation of four experiments.
(a)The coupling efficiency is calculated as: HCHO × 100/NADPH consumed.
(b)The coupling efficiency is calculated as 6β-hydroxytestosterone × 100/NADPH consumed.
NADPH–Cytochrome c Reduction by
3A4-BMR Chimeras
The results from enzymatic activity, coupling and reduction
potentials indicate that the different loops affect the interaction
between the BMR and 3A4 domains of the chimeras, probably
due to the different degrees of length and flexibility associated
with them. Cytochrome c was therefore used as external probe to
check its ability to intercept the electrons of NADPH delivered by
the BMRwhen this is exposed and hence available to interact with
proteins other than the 3A4 domain. The ability of cytochrome c
to be reduced by NADPH via free cytochrome P450 reductase has
already been described in the literature (Guengerich et al., 2009).
The capability of 3A4-BMR chimeras to use NADPH electrons
to reduce cytochrome c is strictly related to cytochrome c ability
to interact directly with the BMR domain when this is exposed.
In order to explore the effect of viscosity on the interaction of
cytochrome c with the chimera BMR domain, we performed
the experiments both in the absence and in the presence of
20% glycerol. The reduction rates were calculated as nmoles of
reduced cytochrome c per min and the results are summarized in
the Figure 5.
The 3A4-5GLY-BMR chimera shows the highest cytochrome
c reduction rate compared to the other two proteins. Moreover,
the presence of 20% glycerol significantly impaired cytochrome c
reduction ability of all the three constructs, with the 3A4-5GLY-
BMR being the most affected one.
DISCUSSION
Cytochromes P450 have been extensively used in our laboratories
to investigate their potential for applications in biocatalysis
as electron transfer domains in chimeric constructs (Cunha
et al., 1999; Sadeghi et al., 2011; Sadeghi and Gilardi, 2013).
This work investigates how the stability and activity of self-
sufficient chimeric human enzymes can be optimized not only by
creating fusion proteins but also with the correct choice of loop
connecting the reductase and the catalytic domains.
The stability of the P450 catalytic domain is significantly
improved in the presence of the BMR domain since all the
three fusion proteins showed a 1.5–2 fold lower rate of P450
loss compared to P450 3A4. In this case, the presence of an
extra domain rather than the length of the loop is essential
for stability as no significant differences are observed among
the three proteins. However, the length of the loop has an
impact on other parameters, such as NADPH oxidation rates
and reduction potential. In particular, the chimeric proteins show
a higer NADPH consumption rate compared to the CYP3A4-
hCPR system at a 1:1 molar ratio. Moreover, the 3A4-3GLY-
BMR protein shows a 2-folds faster rate in NADPH consumption
with respect to the other two constructs. This effect suggests that
the 3GLY construct is more prone to accept electrons from the
redox partner with respect to no GLY and 5GLY leading to a
faster reduction of the heme-Fe3+ to heme-Fe2+ (Sligar et al.,
1979). These data show that there is a critical length of the
linker between the domains that can modulate the inter-domain
interactions that determine the rate of the electron transfer.
The fastest oxidation rate in the 3GLY protein is explained by
its more positive reduction potential compared to the other two
fusion proteins. It is known that in redox proteins, the interaction
with the redox partner can influence the conformation, the
reduction potential and in general, the dielectric environment of
the redox cofactor (Bendall, 1996). Here, the three fusion proteins
show a different, although negative, reduction potential that can
reflect a different dielectric heme environment triggered by a
different domain arrangement and interaction.
When investigating the catalytic domain ability to use
reducing equivalents for erythromycin N-demethylation and
testosterone 6β-hydroxylation during the catalytic event, the
5GLY construct resulted the best for both turnover rate and
coupling efficiency. Thus, the increase in turnover number and
coupling efficiency is neither directly related to an improvement
in electron transfer rate nor to a more positive heme iron
reduction potential. Differences in substrate binding can also
be excluded as the KM-values measured for both erythromycin
and testosterone substrates are similar for the three proteins
and within the range of previously published data (Riley and
Howbrook, 1998; Yuan et al., 2002). Moreover, these data are
consistent with previously published results in which it was
demonstrated that the use of artificial redox chains allows the
regulation of the electron flow to the P450 catalytic domain
through the mediation of the non-physiological reductase
domain by lowering the electron transfer rate and improving
the correct electrochemical inter-domain tuning thus enhancing
coupling efficiency and catalytic activity (Dodhia et al., 2008;
Degregorio et al., 2011; Castrignanò et al., 2014).
In order to investigate if there is a correlation between
the observed improved turnover/coupling efficiency and
an increased inter-domain flexibility in the 5GLY protein,
cytochrome c was used as external probe to check its ability to
Frontiers in Pharmacology | www.frontiersin.org 9 March 2017 | Volume 8 | Article 121
Degregorio et al. Engineering Efficient 3A4-BMR Chimeras
FIGURE 5 | Activity and coupling of the 3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR chimeras toward erythromycin N-demethylation. (A) Catalytic
activity measured as HCHO production rate in the presence of 3A4-BMR (circles), 3A4-3GLY-BMR (triangles) and 3A4-5GLY-BMR (squares) as function of
erythromycin concentration fitted with MichaelisMenten curves. (B) Summary of Vmax-values calculated during erythromycin N-demethylation in the presence of
cytochrome P450 3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR. (C) Summary of coupling percentage values calculated during erythromycin N-demethylation in
the presence of cytochrome P450 3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR. (D) Catalytic activity measured as 6β-hydroxytestosterone production rate in the
presence of 3A4-BMR (circles), 3A4-3GLY-BMR (triangles) and 3A4-5GLY-BMR (squares) as function of testosterone concentration fitted with Michaelis Menten
curves. (E) Summary of Vmax-values calculated during testosterone 6β-hydroxylation in the presence of cytochrome P450 3A4-BMR, 3A4-3GLY-BMR and
3A4-5GLY-BMR. (F) Summary of coupling percentage values calculated during testosterone6β-hydroxylation in the presence of cytochrome P450 3A4-BMR,
3A4-3GLY-BMR and 3A4-5GLY-BMR. All reactions were carried out at 37◦C for 30min. Data are mean ± SD of at least 3 replicates. R2> 0.99. *P < 0.01,
**P < 0.001 compared to 3A4-BMR, #P < 0.05, ##P < 0.001 compared to 3A4-3GLY-BMR, one way ANOVA.
intercept the electrons of NADPH delivered by the BMR when
this is exposed and hence available to interact with proteins
other than the 3A4 domain. The 5GLY resulted in the fastest in
cytochrome c reduction and this result can be explained by the
highest flexibility between the reductase and catalytic domain
of the chimera allowing a better interaction with cytochrome
c and an easier electron delivery from BMR reductase domain
(Figure 6). This interpretation is further confirmed by the fact
that the impairment of inter-domain flexibility upon glycerol
addition that increases the medium viscosity, causes a significant
decrease in the cytochrome c reduction rate in all the three
constructs, with a more marked effect on the more flexible for
5GLY loop.
Taken together, the erythromycin N-demethylation and
testosterone 6β-hydroxylation activity and the coupling results
show that the 3A4-5GLY-BMR chimera is the more catalytically
efficient and the more coupled. This result suggests that the
higher linker flexibility allows a more proficient arrangement of
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catalytic and reductase domains and improves the tuning of the
electron transfer to the active site leading to a more accurate
electrons delivery from the NADPH electron source during the
catalytic event (Figure 7).
FIGURE 6 | Summary of NADPH-cytochrome c reduction rates by
3A4-BMR, 3A4-3GLY-BMR and 3A4-5GLY-BMR chimeras. Data obtained
in the presence of 0% glycerol (black bars) and 20% glycerol (gray bars) are
shown. They are mean ± SD of at least 3 replicates. *P < 0.001 vs. 0%
glycerol; #P < 0.001 vs. 3A4 BMR and 3GLY(two way ANOVA followed by
Student-Newman-Keuls post hoc test).
CONCLUSIONS
The creation of chimeric proteins was shown before to improve
the solubility of P450 3A4 and to generate catalytically self-
sufficient enzymes (Degregorio et al., 2011). Here, the P450
3A4-BMR catalytic performance is improved in terms of
coupling efficiency and enzyme turnover by engineering the loop
connecting the P450 3A4 and the BMR modules. The glycine
linker acts as a flexible hinge that can control electron flow
rate, catalytic activity and coupling efficiency of the 3A4-BMR
chimeras. Data in this work highlight that the modulation of
the length of the linker connecting the modules of a multi-
domain protein has an impact on electron transfer, catalytic
ability and coupling efficiency of the system that can be ascribed
to the modulation of inter-domain flexibility and interactivity
rather than to a different tuning of the electron transfer
process. These parameters can be considered as the major
requirement for an optimization of the electron delivery to the
heme iron center showing that the design of the linker hinge
between the interacting domains plays a crucial role in the
optimization of reductase domain improvement of P450 catalytic
efficiency. Our results suggest that for the 3A4-BMR fusion
proteins studied here, the electron transfer may be achieved
through the direct flow between the reductase and the heme
domain rather than through “inter subunits” interaction between
FIGURE 7 | Model of BMR-P450 active complex formation and interaction in the three different chimeric proteins. The length of the inter-domains loop
favors the formation of different types of complexes that can justify different electron transfer rates, turnover and coupling efficiency. P (proline), S (serine), and R
(arginine) are the three amino acids common to the three chimeras. G is glycine.
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protomers in a dimeric system as suggested for the P450 BM3
system.
This molecular design approach can be successfully developed
for the obtainment of performing enzymatic paradigms
suitable for biotechnological applications. The next step is the
introduction of such catalysts in bacterial cells for the large-scale
production of drug metabolites using whole cells as a less
expensive system.
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